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Abstract
Background: Genetic screening of breast cancer patients and their families have identified a number of variants of 
unknown clinical significance in the breast cancer susceptibility genes, BRCA1 and BRCA2. Evaluation of such 
unclassified variants may be assisted by web-based bioinformatic prediction tools, although accurate prediction of 
aberrant splicing by unclassified variants affecting exonic splice enhancers (ESEs) remains a challenge.
Methods: This study used a combination of RT-PCR analysis and splicing reporter minigene assays to assess five 
unclassified variants in the BRCA2 gene that we had previously predicted to disrupt an ESE using bioinformatic 
approaches.
Results: Analysis of BRCA2 c.8308 G > A (p.Ala2770Thr) by mRNA analysis, and BRCA2 c.8962A > G (p.Ser2988Gly), BRCA2 
c.8972G > A (p.Arg2991His), BRCA2 c.9172A > G (p.Ser3058Gly), and BRCA2 c.9213G > T (p.Glu3071Asp) by a minigene 
assay, revealed no evidence for aberrant splicing.
Conclusions: These results illustrate the need for improved methods for predicting functional ESEs and the potential 
consequences of sequence variants contained therein.
Background
DNA sequence variants of unknown clinical significance
are regularly identified when individuals with a family
history of breast cancer are screened for mutations in the
BRCA1 and BRCA2 genes. Determining the clinical rele-
vance of these unclassified variants, particularly rare
exonic unclassified variants, is challenging. Currently,
functional assays designed to assess the pathogenicity of
exonic unclassified variants usually aim to determine the
effect on protein function, and do not take into account
the potential effect the UV may have on RNA function.
Defects in RNA function, including defects in RNA splic-
ing, stability and translation, are likely to underly the
pathogenicity of a significant proportion of unclassified
variants (reviewed in [1]). For example, sequence variants
in exonic splice enhancers (ESEs) that result in either
abnormal splicing or induce the skipping and therefore
rescue of deleterious non-sense mutations, have previ-
ously been reported in multiple disease-associated genes,
including BRCA1 and BRCA2 [2-6],
Whilst predicting the consequences of unclassified
variants in the consensus donor and acceptor dinucle-
otide sites flanking exons can be done with reasonable
confidence, forecasting the effect of exonic unclassified
variants mapping to ESEs is much more difficult. This is
in part due to fact that ESEs are relatively poorly defined
and the SR proteins involved in recognition of ESEs may
recognize a wide variety of sequences [7]. Several
approaches have been proposed to assist in the identifica-
tion of bona fide active ESEs, including evolutionary con-
servation, distance from the intron-exon boundaries, and
the application of more stringent thresholds when using
bioinformatic prediction tools [4,8,9].
In a previous study [10], our group used the ESE predic-
tion tool ESEfinder to identify total of 1,114 ESEs across
the  BRCA2  transcript. The total number of predicted
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ESEs was reduced to 31 by introducing custom thresh-
olds for four SR proteins involved in enhancer activity,
restricting the length of exonic sequence to the first and
final 125 base pairs (bp), and assessing ESEs for sequence
conservation. Significantly, twenty of these prioritized
ESEs colocalized with unclassified variants reported to
the Breast Cancer Information Core (BIC, http://
research.nhgri.nih.gov/bic/) and the Kathleen Cuning-
ham Foundation Consortium for research into Familial
Breast cancer (kConFab, http://www.kconfab.org). In the
conclusions of our previous paper [10], we recommended
that the unclassified variants prioritised in the study be
experimentally analysed for splicing disruption to verify
the in silico predictions.
In this study we analysed five BRCA2 unclassified vari-
ants that we had previously predicted to either cause loss
o f  a n  E S E  m o t i f  ( d e n o t e d  u s i n g  H G V S  n o m e n c l a t u r e
([11]) as: BRCA2  c.8962A > G (p.Ser2988Gly), BRCA2
c.8972G > A (p.Arg2991His) and BRCA2 c.9213G > T
(p.Glu3071Asp)) or to decrease the score of the predicted
ESE motif (BRCA2  c.9172A > G (p.Ser3058Gly) and
BRCA2 c.8308 G > A (p.Ala2770Thr)) [10]. A source of
RNA was only available for one of these variants (BRCA2
c.8308 G > A (p.Ala2770Thr)), which was analysed for
splicing defects by RT-PCR. For the remaining four, we
used a minigene approach [12-14] to examine the effect
of each variant on splicing.
Methods
LCL mRNA analysis of BRCA2 c.8308 G > A (p.Ala2770Thr)
A lymphoblastoid cell line (LCL) generated from the lym-
phocytes of a patient carrying BRCA2  c.8308 G > A
(p.Ala2770Thr) was obtained from kConFab for mRNA
analysis. RNA was extracted from the LCL as well as two
independent normal control LCLs after treatment with
and without cyclohexamide, utilised to reduce the inci-
dence of nonsense mediated decay (NMD). BRCA2
c.8308 G > A (p.Ala2770Thr) is located in exon 18, and
PCR primers were designed to amplify BRCA2  tran-
scripts from exons 16 to 19. BRCA2  PCRs were per-
formed in 20 μL reactions over 35 cycles with
recombinant Taq, using oligo dT primed cDNA and 40 ng
of each primer. The primers used were designed to
amplify a product spanning exon 18, which harbours the
unclassified variant BRCA2 c.8308 G > A (p.Ala2770Thr)
(Exon 16 for: 5' TGATGGAAAGGCTGGAAAAG-3' and
Exon 19 Rev: 5'-GCAGGCCGAGTACTGTTAGC-3').
Splicing reporter minigene constructs
Minigene constructs containing BRCA2 exons 23, intron
23 and exon 24, along with 120 nucleotides of intron 22
and 134 nucleotides of intron 24, were synthesized by
Genscript (Genscript Corp, NJ) and cloned into the mul-
tiple cloning site of the pSPL3 plasmid (Invitrogen).
pSPL3 is an exon trapping vector that contains a splice
donor and acceptor site and has been widely used to
study the products of pre-mRNA splicing [15]. Minigenes
containing the wild type sequence, a positive control,
which contains a variant (BRCA2  c.9117G > A
(p.Pro3039Pro) known to cause skipping of exon 23 [16],
or the BRCA2  unclassified variants: c.8962A > G
(p.Ser2988Gly), c.8972G > A (p.Arg2991His), c.9172A >
G (p.Ser3058Gly), and c.9213G > T (p.Glu3071Asp) were
generated.
Cell Culture and transfection
MDA-MB-231 cells were maintained using DMEM
(Invitrogen, CA) with 10% foetal bovine serum and 1%
penicillin/streptomycin/anti-mycotic. Cells were pre-
plated 24 hours prior to transfection in antibiotic free
DMEM with 10% foetal bovine serum. Cell cultures were
transfected at 90-95% confluence using Lipofectamine
2000 (Invitrogen, CA) according to the manufacturer's
instructions, with vectors containing each of the con-
structs and a vector only control. Cells were then cultured
for 48 hours before harvesting for RNA analysis.
Reverse transcriptase PCR and sequence confirmation
RNA was extracted using Trizol (Invitrogen, CA) and
treated with DNase to reduce DNA contamination using
DNA-free (Ambion, TX). cDNA was synthesized using
500 ng of DNase treated RNA, using Superscript First
Strand Synthesis System III, according to the manufac-
turer's instructions (Invitrogen, CA). cDNAs correspond-
ing to minigene transcripts were amplified using the
primers SD6 (TCTGAGTCACCTGGACAACC) and SA2
(ATCTCAGTGGTATTTGTGAGC) and Amplitaq Gold
(Applied Biosystems, Victoria, Australia) under the fol-
lowing conditions: 95°C for 5 mins, 35 cycles of 95°C for
30 secs, 55°C for 30 secs and 72°C for 1 min followed by a
final extension step of 72°C for 5 mins. All PCR products
were cloned using pGEM®-T Easy Vector (Promega Cor-
poration, WI) according to the manufacturer's instruc-
tions. Transformant culture (JM109 competent E-coli)
was spread on LB-ampicillin/IPTG/X-gal plates. Recom-
binant clones selected by blue-white selection were
mixed with 5 μl of water and used as DNA template for
PCR under the conditions outlined above, and sequenced
using Big-Dye Terminator version 3.1 sequencing chem-
istry.
Results
No evidence of splicing abnormalities caused by BRCA2 
c.8308 G > A (p.Ala2770Thr)
To determine the consequences of BRCA2 c.8308 G > A
(p.Ala2770Thr) on splicing, we performed RT-PCR anal-
ysis of a lymphoblastoid cell-line (LCL) generated from
the lymphocytes of a patient carrying this UV, and twoWhiley et al. BMC Medical Genetics 2010, 11:80
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LCLs from normal controls. PCR products from all sam-
ples matched in size to the wild-type BRCA2 mRNA and
the previously reported BRCA2-Δ18 [17] (Figure 1).
No evidence of splicing abnormalities caused by BRCA2 
c.8962A > G (p.Ser2988Gly), BRCA2 c.8972G > A 
(p.Arg2991His), BRCA2 c.9172A > G (p.Ser3058Gly), or 
BRCA2 c.9213G > T (p.Glu3071Asp)
To determine the consequences of BRCA2 c.8962A > G
(p.Ser2988Gly),  BRCA2  c.8972G > A (p.Arg2991His),
BRCA2 c.9172A > G (p.Ser3058Gly), and BRCA2 c.9213G
> T (p.Glu3071Asp) on splicing, minigene constructs
containing BRCA2 exons 23 and 24 and flanking intron
sequences, and either wild-type, positive control or
unclassified variant sequences, were introduced into cells
and their respective transcripts analysed by RT-PCR and
DNA sequencing. As expected, a normal splicing product
containing exons 23 and 24 was observed for the wild-
type constructs, whereas a smaller product containing
exon 24 only was observed upon analysis of the positive
control BRCA2 c.9117G > A (p.Pro3039Pro), which has
been previously reported to induce aberrant splicing (Fig-
ure 2). Sequence analysis also revealed that PCR products
contained an additional 115 base pair sequence, which
corresponded to a cryptic exon derived from intronic
sequence downstream from the multiple cloning site
within the vector, and which has been reported previ-
ously [18]. Analysis of the minigenes containing each of
the four tested unclassified variants resulted in PCR
products that were indistinguishable from that generated
by the wild-type construct (Figure 2). Sequence analysis
of the PCR product confirmed the presence of the unclas-
sified variant sequence (data not shown).
Discussion
This study analysed the pre-mRNA splicing patterns
associated with the presence of five BRCA2 unclassified
variants colocalising with and predicted to disrupt con-
served ESEs. Unexpectedly, we found no evidence for
altered splicing associated with any of these unclassified
variants. For the UV analysed using an LCL, possible
explanations for the lack of aberrant splicing include that
the effects of the UV are only evident in mammary epi-
thelia and not lymphoblastoid cells, although there are
multiple precedents for using LCL RT-PCR analysis to
identify pathogenic splicing abnormalities [19]. Possible
explanations for the lack of aberrant splicing caused by
u n c l a s s i f i e d  v a r i a n t s  i n t r o d u c e d  i n t o  o u r  m i n i g e n e
include that the unclassified variants actually affect ESEs
that regulate splicing of exons not included in the mini-
gene construct, or that the effect of the UV on the ESE is
dependent on a splicing factor that is not expressed or
fully functional in the cell-line that was used in these
studies. The fact that our positive and negative controls
worked in both the minigene experiments and that previ-
ous studies have shown concordance between results
obtained from minigene assays using cells from a tissue
not related to the target [14], suggest that these possibili-
ties are unlikely to explain our results.
A more plausible explanation for our data is that the
ESEs predicted bioinformatically are not true ESEs, and
thus that the unclassified variants analysed in this paper
do not have any effect on splicing. This would suggest
that, despite efforts to reduce the level of false positives
identified by current bioinformatic prediction programs
[8,10], the accuracy of these programs has yet to
Figure 1 No evidence for altered splicing of transcripts derived 
from an LCL generated from a BRCA2 c.8308 G > A (p.Ala2770Thr) 
carrier. LCLs from a carrier of BRCA2 c.8308 G > A (p.Ala2770Thr) or two 
BRCA2 normal LCL controls were analysed by RT-PCR using primers 
specific for BRCA2 exons 16 and 19. CHX indicates cycloheximide treat-
ment, which was used to examine transcript stability, RT indicates re-
verse transcriptase. N indicates no template control.
Figure 2 No evidence for altered splicing of transcripts derived 
from minigenes incorporating the BRCA2 unclassified variants: 
c.8962A > G (p.Ser2988Gly), c.8972G > A (p.Arg2991His), c.9172A 
> G (p.Ser3058Gly), and c.9213G > T (p.Glu3071Asp). RT-PCR prod-
ucts from duplicate cell culture experiments for each minigene con-
struct and a vector only control. The vector only sample does not 
contain an insert and therefore produces a 261 bp band made up of 
fragments of pSPL3 constitutive exons. The positive control, BRCA2 
c.9117G > A (p.Pro3039Pro) produces a 410 bp band representing the 
vector exons and BRCA2 exon 24. The higher molecular weight band in 
all samples includes a 115 bp cryptic exon. The 574 bp band seen in all 
unclassified variants and the wildtype represents the vector exons and 
BRCA2 exons 23 and 24. Negative controls include: 1. No reverse tran-
scriptase in cDNA synthesis of the wild type construct; 2. No template 
for the PCR; 3. Negative control for transfection. Fragments resolved 
1.5% agarose gel stained with ethidium bromide.Whiley et al. BMC Medical Genetics 2010, 11:80
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approach the levels necessary for application in clinical
scenarios. It has certainly been recognised that attempts
to predict the site of ESEs are often confounded not only
by the high level of variability accommodated by motifs
[7], but also because ESE function is defined by additional
factors, such as the distance from the splice site and splice
site strength [20]. Consistent with this, different predic-
tion programs regularly produce conflicting results [21].
The incorporation of evolutionary conservation filtering
on ESE prediction improved the colocalization with
reported unclassified variants [10] however, this may in
fact reflect the pressure to maintain amino acid sequence
rather than an ESE sequence.
The results of this study are supported by other studies
demonstrating the validity of minigene reporter assays
for analysing pre-mRNA splicing associated with DNA
sequence variants [13,14,21], particularly when patient
peripheral blood or LCLs are unavailable for RNA analy-
sis [19]. An additional advantage of minigene assays is
that the effect on splicing produced by a variant allele can
be isolated from the influence of a wild type allele.
Conclusions
The increased reporting of rare sequence variants with
routine sequencing of high-risk genes in BRCA1  and
BRCA2 has resulted in increased reporting of unclassified
variants, a situation that will be exacerbated for all dis-
ease-predisposition genes as deep sequencing becomes
more affordable for clinical testing laboratories. Web-
based splice prediction tools have an important role in
assessing and prioritizing variants for analysis using
experimental methods. Validating predictions using in
vitro techniques will provide valuable data for the devel-
opment of in silico tools, particularly those for ESEs
where prediction accuracy is currently very poor
[10,12,13,21]. Improving the predictive capabilities of
web-based programs is essential before they can be util-
ised for large scale prioritisation of variants for assays, or
for the long-term goal of prediction at the clinical level.
Our results demonstrate the difficulty in predicting the
impact on splicing of sequence variation within putative
ESEs, and stress the importance of experimental valida-
tion of bioinformatic predictions.
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